3D culture of human breast cancer cells, with DNA stained blue and a protein in the cell surface membrane stained green. Credit: Tom Misteli, PhD, and Karen Meaburn, PhD.

Israeli researchers have combined commercially existing, inexpensive breath and urines tests to accurately detect biomarkers of breast cancer in early stages.

The team from Ben-Gurion University of the Negev and Soroka University Medical Center used two different electronic nose (e-nose) gas sensors to analyse breath and gas-chromatography mass spectrometry (GC-MS) for quantification of substances in urine.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

While the e-nose demonstrated an average of 95% accuracy in detecting unique breath patterns in breast cancer patients, a revamped GC-MS had 85% average accuracy for statistical analyses of urine samples.

“The team researchers used two different electronic nose (e-nose) gas sensors to analyse breath and gas-chromatography mass spectrometry (GC-MS) for quantification of substances in urine.”

Ben-Gurion University Biomedical Engineering department professor Yehuda Zeiri said: “Breast cancer survival is strongly tied to the sensitivity of tumour detection; accurate methods for detecting smaller, earlier tumours remain a priority.

“Our new approach utilising urine and exhaled breath samples, analysed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.”

Current approaches for the diagnosis of breast cancer are said to have significant drawbacks such as more radiation exposure with dual-energy digital mammography, and invasive biopsies.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Even though mammography screenings were found to significantly decrease breast cancer related mortality rates, they are limited due to an incapability to identify small tumours in dense breast tissue.

Zeiri added: “We’ve now shown that inexpensive, commercial electronic noses are sufficient for classifying cancer patients at early stages.

“With further study, it may also be possible to analyse exhaled breath and urine samples to identify other cancer types, as well.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact